148 related articles for article (PubMed ID: 38560576)
1. Investigation of the feasibility of NRAV as a biomarker for hepatocellular carcinoma.
Liu J; Li W; Lu R; Xu J; Jiang C; Duan J; Zhang L; Wang G; Chen J
Oncol Res; 2024; 32(4):717-726. PubMed ID: 38560576
[TBL] [Abstract][Full Text] [Related]
2. Long non-coding RNA NRAV enhances proliferation and invasion of hepatocellular carcinoma cells by modulating the Wnt/β-catenin signaling pathway.
Wang Q; Tang Y; Ge Y; Zhang S; Zheng M
Bioengineered; 2022 Apr; 13(4):10026-10037. PubMed ID: 35436415
[TBL] [Abstract][Full Text] [Related]
3. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma.
Xu Q; Wang Y; Huang W
Int Immunopharmacol; 2021 Mar; 92():107333. PubMed ID: 33486322
[TBL] [Abstract][Full Text] [Related]
4. ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion.
Huang S; Dong C; Li D; Xu Y; Wu J
Front Cell Dev Biol; 2022; 10():896080. PubMed ID: 35733852
[No Abstract] [Full Text] [Related]
5. The Prognostic and Immunotherapeutic Significance of AHSA1 in Pan-Cancer, and Its Relationship With the Proliferation and Metastasis of Hepatocellular Carcinoma.
Li W; Liu J
Front Immunol; 2022; 13():845585. PubMed ID: 35757728
[TBL] [Abstract][Full Text] [Related]
6. Lipophagy-related gene RAB7A is involved in immune regulation and malignant progression in hepatocellular carcinoma.
Liu Y; Ma J; Wang X; Liu P; Cai C; Han Y; Zeng S; Feng Z; Shen H
Comput Biol Med; 2023 May; 158():106862. PubMed ID: 37044053
[TBL] [Abstract][Full Text] [Related]
7. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment.
Gao B; Wang Y; Lu S
Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232
[TBL] [Abstract][Full Text] [Related]
8. Cyclin-Dependent Kinase 4 is expected to be a therapeutic target for hepatocellular carcinoma metastasis using integrated bioinformatic analysis.
Zhang JN; Wei F; Lei LH; Yang Y; Yang Y; Zhou WP
Bioengineered; 2021 Dec; 12(2):11728-11739. PubMed ID: 34784846
[TBL] [Abstract][Full Text] [Related]
9. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
Huang S; Sun L; Hou P; Liu K; Wu J
Front Immunol; 2022; 13():944898. PubMed ID: 36148220
[TBL] [Abstract][Full Text] [Related]
10. Intergrated analysis of ELMO1, serves as a link between tumour mutation burden and epithelial-mesenchymal transition in hepatocellular carcinoma.
Peng H; Zhang Y; Zhou Z; Guo Y; Huang X; Westover KD; Zhang Z; Chen B; Hua Y; Li S; Xu R; Lin N; Peng B; Shen S
EBioMedicine; 2019 Aug; 46():105-118. PubMed ID: 31324602
[TBL] [Abstract][Full Text] [Related]
11. ADNP is associated with immune infiltration and radiosensitivity in hepatocellular carcinoma for predicting the prognosis.
Wang X; Peng H; Zhang G; Li Z; Du Z; Peng B; Cao P
BMC Med Genomics; 2023 Jul; 16(1):178. PubMed ID: 37525242
[TBL] [Abstract][Full Text] [Related]
12. [Pan-cancer analysis of the expression pattern of long non-coding RNA MIR22HG].
Wang H; Li W; Zhang D
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Apr; 42(4):473-485. PubMed ID: 35527483
[TBL] [Abstract][Full Text] [Related]
13. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
[TBL] [Abstract][Full Text] [Related]
14. Systematic analysis of the role of LDHs subtype in pan-cancer demonstrates the importance of LDHD in the prognosis of hepatocellular carcinoma patients.
Wang S; Wu X; Wu X; Cheng J; Chen Q; Qi Z
BMC Cancer; 2024 Jan; 24(1):156. PubMed ID: 38291366
[TBL] [Abstract][Full Text] [Related]
15. Crosstalk of cuproptosis-related prognostic signature and competing endogenous RNAs regulation in hepatocellular carcinoma.
Zhu J; Wang J; Liu H; Lei T; Yang J; Lan S; Jian H; Fang H; Zhang Y; Ren K; Zhong F
Aging (Albany NY); 2023 Dec; 15(23):13901-13919. PubMed ID: 38078880
[TBL] [Abstract][Full Text] [Related]
16. Overexpressed GNAZ predicts poor outcome and promotes G0/G1 cell cycle progression in hepatocellular carcinoma.
Tian F; Cai D
Gene; 2022 Jan; 807():145964. PubMed ID: 34530087
[TBL] [Abstract][Full Text] [Related]
17. Identification of a Novel N7-Methylguanosine-Related LncRNA Signature Predicts the Prognosis of Hepatocellular Carcinoma and Experiment Verification.
Yang C; Zhang L; Hao X; Tang M; Zhou B; Hou J
Curr Oncol; 2022 Dec; 30(1):430-448. PubMed ID: 36661684
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma.
Zhang H; Qiu C; Zeng H; Zhu W; Lyu W; Lao X
Genet Test Mol Biomarkers; 2021 Jul; 25(7):504-514. PubMed ID: 34280005
[No Abstract] [Full Text] [Related]
19. The Pyroptosis-Related Signature Composed of GSDMC Predicts Prognosis and Contributes to Growth and Metastasis of Hepatocellular Carcinoma.
Li M; Jiang Q; Liu X; Han L; Chen S; Xue R
Front Biosci (Landmark Ed); 2023 Oct; 28(10):235. PubMed ID: 37919059
[TBL] [Abstract][Full Text] [Related]
20. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
